THE OFF- LABEL USE OF CARBAMAZEPINE IN INDONESIA

Bangunawati Rahajeng; Zullies Ikawati; Tri Murti Andayani; Iwan Dwiprahasto

doi:10.22159/ajpcr.2018.v11i5.20682

Authors

Bangunawati Rahajeng Faculty of Pharmacy. Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.
Zullies Ikawati Departement of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Tri Murti Andayani Departement of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Iwan Dwiprahasto Departement of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i5.20682

Keywords:

anticonvulsant, carbamazepine, indications, off-label

Abstract

Â Objective:. In Indonesia, carbamazepine was approved by The National Agency of Drugs And Foods Controls for the prophylaxis of lithium unresponsive manic-depressive disorders, all types of epilepsy (except for petit mal), and trigeminal neuralgia. This study was conducted to determine the off-label use of carbamazepine in Indonesia.

Methods: This research is a nonexperimental descriptive study with a cross-sectional method. Data collection retrospectively by taking all patients that were prescribed carbamazepine in 2014. Data were obtained from four general hospitals in Yogyakarta. The off-label use of carbamazepine was defined a prescribing of carbamazepine outside the indication that approved by The National Agency for Drugs And Foods Controls of Republic of Indonesia (NA-DFC).

Results: The use of carbamazepine in 2014 were 704 prescriptions, and on 251 (35.6%) of them were off-label drug use. The off-label use of carbamazepine were 149 prescriptions (59.4%) for neuropathic pain, 83 prescriptions (33.0%) for nociceptive pain, and 19 prescriptions (7.6%) for other indications.

Conclusion: The mostly off-label use of carbamazepine in Indonesia was in neuropathic pain with low evidence. Further research to study the efficacy and the risk of off-label use of carbamazepine may be an essential step toward defining the potential for such purpose.

Downloads

Download data is not yet available.

Author Biography

Bangunawati Rahajeng, Faculty of Pharmacy. Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.

Departement of Pharmacology and Clinical Pharmacy School of Pharmacy

Faculty of Medical and Health Sciences

Universitas Muhammadiyah Yogyakarta

Doctoral Student of Faculty of Pharmacy Universitas Gadjah Mada Yogyakarta Indonesia

References

Gazarian M. Off-Label Use of Medicines in the Paediatric Poulation: Recommendations for Assesing Appropriateness. NSW, 2031. Sydney, Australia: NSW; 2007.

Knopf H, Wolf IK, Sarganas G, Zhuang W, Rascher W, Neubert A. Off-label medicine use in children and adolescents: Results of a population-based study in Germany. BMC Public Health 2013;13:631.

Campbell T, Gandecha K, Gazarian M, Graudins L, Kelly M, MacDonald J, et al. Off-label Use of Registered Medicines and Use of Medicines Under the Personal Importation Scheme in NSW Public Hospitals, an Initiative of NSW Clinical Pharmacologists and Pharmacists Funded by the NSW Department of Health; 2003.

Ferreira LA, Ibiapina C, Machado MG, Fagundes ED. High prevalence of off-label and unlicensed drug prescribing in a Brazilian intensive care unit. Rev Assoc MÃ©d Bras Engl Ed 2012;58:82-7.

Stafford RS. Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med 2008;358:1427-9.

Backonja MM. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000;16 2 Suppl:S67-72.

Vargas-Espinosa M, Sanmarti-Garcia G, Vazquez-Delgado E, Gay-Escoda C. Antiepileptic drugs for the treatment of neuropathic pain: A systematic review. Med Oral Patol Oral Cirugia Bucal 2012;17:e786-93.

Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice AS, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia-an overview of cochrane reviews. In: The Cochrane Collaboration, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd.; 2013. Available from: http://www.doi.wiley.com/10.1002/14651858.CD010567.pub2. [Last cited on 2015 Mar 03].

Mendlik MT, Uritsky TJ. Treatment of neuropathic pain. Curr Treat Options Neurol 2015;17:50. Available from: http://www.link.springer.com/10.1007/s11940-015-0381-2. [Last cited on 2015 Nov 20].

AmbrÃ³sio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002;27:121-30.

Besi E, Boniface DR, Cregg R, Zakrzewska JM. Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the liverpool adverse events profile (AEP). J Headache Pain 2015;16. Available from: http://www.thejournalofheadacheandpain.com/content/16/1/81. [Last cited on 2016 Jan 02].

Spina E, Perugi G. Antiepileptic drugs indications other than epilepsy. Epileptic Dissorder 2004;6:57-75.

Leijon G, Boivie J. Central post-stroke pain-a controlled trial of amitriptyline and carbamazepine. Pain 1989;36:27-36.

Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain Lond Engl 2002;6 Suppl A:61-8.

Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced stevens-johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. JAMA Dermatol 2013;149:1025.

Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. In: The Cochrane Collaboration, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd.; 2014. Available from: http://www.doi.wiley.com/10.1002/14651858.CD005451.pub3. [Last cited on 2015 Nov 20].

Yuan M, Zhou HY, Xiao ZL, Wang W, Li XL, Chen SJ, et al. Efficacy and safety of gabapentin versus carbamazepine in the treatment of trigeminal Neuralgia: A meta-analysis. Pain Pract 2016.

GÃ³mez-PÃ©rez FJ, Choza R, RÃos JM, Reza A, Huerta E, Aguilar CA, et al. Nortriptyline-fluphenazine versus carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996;27:525-9.

Jia H, Li Q, Song D, An Z, Liu Y, Ran X, et al. Effects of veniafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized-double-blind and double-dummy, controlled multi-center trial. Chin J Evid Based Med 2006;6:321-7.

Rull JA, Quibrera R, GonzÃ¡lez-MillÃ¡n H, CastaÃ±eda OL. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): Double blind crossover trial. Diabetologia 1969;5:215-8.

Wilton TD. Tegretol in the treatment of diabetic neuropathy. S Afr Med J Suid Afr Tydskr Vir Geneeskd 1974;48:869-72.

Maheshwary N, Saeed T, Nasrullah M, Ghafoor A, Shahid R, Islam N, et al. Efficacy and tolerability of carbamazepine for the treatment of painful diabetic neuropathy in adults: A 12-week, open-label, multicenter study. Int J Gen Med 2014;339:69-75.

NICE. Neuropathic-Pain-Pharmacological- Management-Full-Guideline- 191621341, National Institute for Health and Care Excellence; 2013. Available from: https://www.nice.org.uk/guidance/cg173/evidence/neuropathic-pain-pharmacological-management-full-guideline-191621341. [Last cited on 2016 Oct 13].

Jena SS, Jena M, Patro N, Mishra S, Panda M, Dash M. Patterns of prescription and ADR monitoring of drugs in the management of neuropathic pain in a tertiary care teaching hospital. Int J Pharm Pharm Sci 2014;6:246-51.

Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009;139:267-84.

Post RM. Time course of clinical effects of carbamazepine: Implications for mechanisms of action. J Clin Psychiatry 1988;49 Suppl:35-48.

Goodnick PJ. Anticonvulsant strategies for treating bipolar disorder: What works, what doesnâ€™t. Psychiatr Times 2014;31:51-1.

Kaufman KR. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav 2011;21:1-11.

Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, et al. Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: A 30-year observational study. Am J Psychiatry 2012;169:285-91.

Varghese AP, Philip B, Krihnakumar M, Kuriakose F, Rodrigues PA. Assessment of osteoporosis and anaemia risk in patients on anticonvulsant therapy. Int J Pharm Pharm Sci 2016;8:404-8.

Onyenwenyi AJ. Off-Label Prescribing of Anticonvulsant Drugs (Desertasi), (Florida, United States): University of Florida; 2008. Available from: http://www.ufdcimages.uflib.ufl.edu/UF/E0/02/19/71/00001/onyenwenyi_a.pdf. [Last cited on 2016 Dec 14].